Physician profile
Lori Moore Langdon
NPI 1649260043
$2,377.92
in general payments reported to CMS, 2019-2025
19 companies · $93.74 in 2025
The $93.74 reported for 2025 was less than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $199 · 2020: $52.89 · 2021: $62.83 · 2022: $111 · 2023: $59.90 · 2024: $1,799 · 2025: $93.74.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,592 · Food and Beverage: $360.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,592.00 |
| Food and Beverage | $360.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $1,655.26 | 2019-2024 | |
| Pfizer INC. | $154.59 | 2019-2024 | |
| Cranial Technologies, INC | $85.96 | 2019-2024 | Doc Band |
| Merck Sharp & Dohme LLC | $63.07 | 2022-2024 | Gardasil 9, Gardasil, Vaxneuvance |
| Novo Nordisk INC | $59.39 | 2025 | Wegovy |
| Verrica Pharmaceuticals INC. | $38.68 | 2024 | Ycanth |
| Kaleo, INC. | $38.38 | 2019 | |
| Endo Pharmaceuticals INC. | $38.35 | 2021-2022 | |
| Ironshore Pharmaceuticals INC. | $32.54 | 2019-2020 | |
| Ermi LLC | $31.03 | 2022 | |
| Sanofi-Aventis U.S. LLC | $29.88 | 2024 | |
| Bioventus LLC | $27.93 | 2021 | |
| Rhythm Pharmaceuticals, INC. | $25.97 | 2024 | Imcivree |
| Sobi, INC | $25.85 | 2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.68 | 2025 | Caplyta |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $13.69 | 2019 | |
| Roche Diagnostics Corporation | $13.67 | 2025 | Cobas Liat Analyzer |
| Glaxosmithkline, LLC. | $12.26 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $10.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Langdon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.